Figure 1From: Epigenetic inactivation of the MIR129-2 in hematological malignanciesMethylation of MIR129-2. (A) Schematic diagram showing the distribution of CpG dinucleotides (solid vertical lines) along precursor MIR129-2 and its upstream promoter region. Region of MSP amplification was indicated by the text box marked as “MSP”. Sequence analysis of the MIR129-2 M-MSP product from bisulfite-treated methylated control DNA showed that the cytosine [C] residues of CpG dinucleotides were methylated and remained unchanged, whereas all the other C residues were unmethylated and were converted to thymidine [T], indicating complete bisulfite conversion and specificity of MSP. (B) Sensitivity of the methylated-MSP for the MIR129-2. (C) M- & U-MSP of 15 healthy donor controls showing no MIR129-2 methylation. (D) All myeloma cell lines, except RPMI-8226, were partially methylated, while RPMI-8226 was completely unmethylated for MIR129-2. (E) All five lymphoma cell lines were completely methylated for MIR129-2.Back to article page